ANGEL ONE

(₹20/Trade)

Open Account

MOTILAL OSWAL

Open Account

Stock Market Institue

Trial Class

Book Now

IPOs, NCDs, OFS, Rights Issues, Buyback and Stock Brokers

Mainboard IPOs & FPOS SME IPOs & FPOS NCD Issues Rights Issues IPO Reports Stock Broker Stock Report

Goldline Pharmaceutical IPO Details

Bookbuilding IPO | ₹12 Cr | Listing at BSE SME | Tue, May 12, 2026 - Thu, May 14, 2026

Goldline Pharmaceutical IPO is a book build issue of ₹11.61 crores. The issue is entirely a fresh issue of 0.27 crore shares of ₹11.61 crore.

Goldline Pharmaceutical IPO opens for subscription on May 12, 2026 and closes on May 14, 2026. The allotment for the Goldline Pharmaceutical IPO is expected to be finalized on May 15, 2026. Goldline Pharmaceutical IPO will list on the BSE SME with a tentative listing date fixed as May 19, 2026.

Goldline Pharmaceutical IPO is set issue price band at ₹41 to ₹43 per share. The lot size for an application is 3,000 shares. The minimum amount of investment required by an individual investor (retail) is ₹2,58,000 (6,000 shares) (based on upper price). The minimum lot size for investment in HNI is 3 lots (9,000 shares), amounting to ₹3,87,000.

Cumulative Capital Pvt.Ltd. is the book running lead manager and Bigshare Services Pvt.Ltd. is the registrar of the issue.

Refer to Goldline Pharmaceutical IPO DRHP for detailed Information.

IPO Open

Tue, May 12, 2026

IPO Close

Thu, May 14, 2026

Price Band

₹41 to ₹43

Market Cap (Pre-IPO)

₹41.28 Cr

IPO Details

IPO Date

12 to 14 May, 2026
Listing Date

Tue, May 19, 2026T
Face Value

₹10 per share
Price Band

₹41 to ₹43
Lot Size

3,000 Shares
Sale Type

Fresh capital only
Issue Type

Bookbuilding IPO
Listing At

BSE SME

Total Issue Size

27,00,000 shares (agg. up to ₹12 Cr)
Reserved for Market Maker

1,38,000 shares (agg. up to ₹0.5934 Cr)
Fresh Issue (Ex Market Maker)

25,62,000 shares (agg. up to ₹11 Cr)
Net Offered to Public

25,62,000 shares (agg. up to ₹11 Cr)
Share Holding Pre Issue

69,00,000 shares
Share Holding Post Issue

96,00,000 shares

IPO Timetable (Tentative)

IPO Open

Tue, May 12, 2026
Allotment

Fri, May 15, 2026
Credit of Shares

Mon, May 18, 2026

IPO Close

Thu, May 14, 2026
Refund

Mon, May 18, 2026
Listing

Tue, May 19, 2026

Goldline Pharmaceutical SME IPO Day-wise GMP Trend

GMP Date

IPO Price

GMP

Subscription

Est. Listing Price

Est. Profit*

Last Updated
07-05-2026

₹43.00

₹0 ─

₹ (%)

7-May-2026 9:30

* Estimated Profit/Loss per lot. GMP × Market Lot.

IPO Live GMP NEW Comprehensive GMP History

Issue Reservation

Goldline Pharmaceutical IPO comprises a total issue size of 1,38,000 shares. The net offer to the public is 0 shares, after excluding 1,38,000 shares allotted on a firm basis. Of the Net offer .

Investor Category	Shares Offered
Firm Reservations
Market Maker Shares Offered	1,38,000
Total Shares Offered	1,38,000

IPO Lot Size

Investors can bid for a minimum of 6,000 shares and in multiples of 3,000 shares thereof.

Application	Lots	Shares	Amount
Individual investors (Retail) (Min)	2	6,000	₹2,58,000
Individual investors (Retail) (Max)	2	6,000	₹2,58,000
S-HNI (Min)	3	9,000	₹3,87,000
S-HNI (Max)	7	21,000	₹9,03,000
B-HNI (Min)	8	24,000	₹10,32,000

IPO Subscription Details

About Goldline Pharmaceutical Ltd.

Goldline Pharmaceuticals is engaged in the business of marketing pharmaceutical products under the brand name “Goldline.” Its product range is divided into five segments:

Goldline Pharma: This category includes 42 products to cater to specialties like Physicians, Orthopedics, ENT, Chest Physicians, General and Specialty Surgery, Gastroenterology, Neurology, and Urology.
Goldline Cardinal: This category offers 54 products tailored for the Specialty division, serving medical fields such as Physicians, Diabetologists, Endocrinologists, Cardiologists, and General Physicians.
Goldline Aayushman: This category comprises 18 products designed for the Specialty division, catering to medical fields such as Pediatricians, Child Specialists, Neonatologists, and General Practitioners.
Goldline InLife: This category includes 22 products tailored for the Specialty division, serving Intensivists, Critical Care Consultants, Super Specialty Surgeons, and Physicians.
Goldline Wellness: This category includes 10 products tailored Supportive care plays a crucial role in cancer therapy.

The company do not manufacture products, it partner with third-party manufacturers who produce the medicines based on its market research and product specifications, ensuring quality and compliance with regulations.

All products are marketed and sold under the Goldline brand through our network of distributors, who supply to retailers and wholesalers. The company currently works with 15 manufacturers and 7 distributors, and it also support hospitals and healthcare providers with procurement and material supply.

The company sells products across the states of Maharashtra, Madhya Pradesh, Odisha, Jharkhand, Tamil Nadu, Rajasthan, and Bihar.

Competitive Strengths:

Experienced Promoters and Management Team with Industry Knowledge and a Track Record
Asset-light Business Model and Competitive Products
Scalable Business Model
Wide and Diverse Range of Product Offerings
Strong Supplier and Vendor Relationships
Established Distribution Network

Company Financials (Restated)

Goldline Pharmaceutical Ltd.’s revenue increased by 19% and profit after tax (PAT) rose by 57% between the financial year ending with March 31, 2025 and March 31, 2024.

Period Ended	31 Mar 2025	31 Mar 2024	31 Mar 2023
Assets	26.28	22.93	19.39
Total Income	28.06	23.57	19.85
Profit After Tax	2.83	1.81	0.26
EBITDA	5.83	4.30	2.19
NET Worth	10.35	7.87	5.89
Reserves and Surplus	1.65	3.76	2.08
Total Borrowing	11.03	11.13	10.83
Amount in ₹ Crore

IPO Objects of the Issue

The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:

# Issue Objects

Est Amt (₹ Cr.)
1 Prepayment or repayment of all or a portion of certain outstanding borrowings availed by our company

8.90
4 General corporate purposes

Key Performance Indicator (KPI)

KPI	Mar 31, 2025
ROE	35.84%
ROCE	38.46%
Debt/Equity	1.50
RoNW	27.38%
PAT Margin	10.10%
EBITDA Margin	20.79%
Price to Book Value	3.47

Check IPO Peer Comparison here.

	Pre IPO	Post IPO
EPS (₹)	4.11	2.95
P/E (x)	10.47	14.56
Promoter Holding	79.70%
Market Cap	₹41.28 Cr.

Amol Laxmikant Mujumdar and Swapan Premprakash Khandelwal are the company promoters.

The value will be calculated using Equity Dilution = Share Holding Pre Issue – Share Holding Post Issue
The Pre IPO EPS is calculated based on Pre issue shareholding as on date of RHP and the latest FY earnings as of March 31, 2025 available in RHP.
The Post Issue EPS is calculated based on the Post issue shareholding and annualized FY earnings of March 31, 2025 available in RHP.

IPO Registrar

Bigshare Services Pvt.Ltd.

+91-22-6263 8200
ipo@bigshareonline.com
Visit Website

IPO Lead Manager(s)

Cumulative Capital Pvt.Ltd. (Past IPO Performance)

Lead Manager Reports

Lead Manager Performance Summary
Lead Manager Performance Tracker

Contact Details

Goldline Pharmaceutical Ltd. Address

103, F-1, Leela Apartment, Shilpa HSG Society,

Near Saptagiri Nagar, Shanidham,

Narendra Nagar,

Nagpur, Maharashtra, 440015

+91 712 2786666
info@goldlinepharma.in
Visit Website

IPO FAQs

What is the Goldline Pharmaceutical IPO?

Goldline Pharmaceutical IPO is a SME IPO of 27,00,000 equity shares of the face value of ₹10 aggregating up to ₹12 Crores. The issue is priced at ₹41 to ₹43. The minimum order quantity is 3000.

The IPO opens on Tue, May 12, 2026, and closes on Thu, May 14, 2026.

Bigshare Services Pvt.Ltd. is the registrar for the IPO. The shares are proposed to be listed on BSE SME.

How to apply in Goldline Pharmaceutical IPO through Angel One?

Angel One customers can apply online in Goldline Pharmaceutical IPO using UPI as a payment gateway. Angel One customers can apply in Goldline Pharmaceutical IPO by login into Angel One Console (back office) and submitting an IPO application form.

Steps to apply in Goldline Pharmaceutical IPO through Angel One

Visit the Angel One website and login to Console.
Go to Portfolio and click the IPOs link.
Go to the ‘Goldline Pharmaceutical IPO’ row and click the ‘Bid’ button.
Enter your UPI ID, Quantity, and Price.
Submit IPO application form.
Visit the UPI App (net banking or BHIM) to approve the mandate.
Visit Angel One IPO Application Process Review for more detail.

When Goldline Pharmaceutical IPO will open?

The Goldline Pharmaceutical IPO opens on Tue, May 12, 2026 and closes on Thu, May 14, 2026.

What is the lot size of Goldline Pharmaceutical IPO?

Goldline Pharmaceutical IPO lot size is 3000, and the minimum amount required for application is ₹2,58,000, with 2 lots being the minimum application size.

How to apply for Goldline Pharmaceutical IPO?

You can apply in Goldline Pharmaceutical IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don’t offer banking services. Read more detail about applying IPO online through Angel One , Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.

When is Goldline Pharmaceutical IPO allotment?

The finalization of Basis of Allotment for Goldline Pharmaceutical IPO will be done on Friday, May 15, 2026, and the allotted shares will be credited to your demat account by Mon, May 18, 2026. Check the Goldline Pharmaceutical IPO allotment status.

When is Goldline Pharmaceutical IPO listing date ?

The Goldline Pharmaceutical IPO listing date is not yet announced. The tentative date of listing is Tue, May 19, 2026.